- For the first time, Fresenius Medical Care develops and
utilizes "Augmented Reality" (AR) to train medical staff in
Intensive Care Units (ICUs)
- The new training application for ICU staff combines digital
learning elements with real-life training on the Fresenius Medical
Care Continuous Kidney Replacement Therapy system
- This learning experience reinforces initial training, a
supplement to support new staff amidst the high fluctuation of
specialists in intensive care nursing
BAD HOMBURG, Germany, March 19,
2024 /PRNewswire/ -- Fresenius Medical Care (FME),
the world's leading provider of products and services for
individuals with renal diseases, launches a new "Augmented Reality"
(AR) application to make learning easier for nursing staff in
Kidney Replacement Therapy in Intensive Care Units. The AR glasses,
in combination with digital learning modules, allow nursing staff
to learn how to use acute dialysis machines on site within the
intensive care wards. The glasses stream visual and acoustic
recordings as users interact with the dialysis machine, providing
professionals with an immersive learning experience.
"We have a dedicated focus on leveraging advanced technology to
develop and provide the most innovative technologies, engineered to
facilitate and simplify the learning process. Our innovative
solution is designed to ensure that nursing staff, particularly
those in Intensive Care Units, are equipped with the knowledge
needed to provide high-quality and exceptional patient care," says
Dr. Katarzyna Mazur-Hofsäß, member of the Management Board
of Fresenius Medical Care AG and responsible for Care Enablement,
Fresenius Medical Care's MedTech segment.
The AR glasses allow for self-guided, on-demand education for
critical care professionals. For example, users train how to set up
the machine, how to activate the citrate pump or how to handle
several system components through the AR training. The AR glasses
provide access to the Augmented Reality learning program
Ready4 multiFiltratePRO AR, which Fresenius
Medical Care presented today at the International Symposium on
Intensive Care and Emergency Medicine (ISICEM) in Brussels.
The AR training application, Ready4
multiFiltratePRO AR, will be launched in select
markets as early as Q2 2024 and subsequently made available to
further countries in the company's Europe, Middle
East and Africa as well as
Asia Pacific regions. A limited
launch of the multiFiltratePRO will take place in
the United States later this year.
Upon successful completion of the Safety of Regional Citrate
Anticoagulation (SARCA) trial, a full launch of the
multiFiltratePRO with the Ready4
multiFiltratePRO AR learning experience is planned
for 2025.
Nursing shortages in the ICU, in particular high staff turnover
rates and staff taking on new tasks at short notice, are a
significant concern in hospitals and healthcare systems worldwide.
This training approach aims to address the challenges the industry
is currently facing and to support the increasing demand for
flexible, high-quality ongoing education to reinforce basic
training.
Ready4 multiFiltratePRO AR has been
specifically developed for use with the multiFiltratePRO,
Fresenius Medical Care's Continuous Kidney Replacement Therapy
system. Today, the multiFiltratePRO is used in more than 40
countries globally.
To learn more about
the Ready4 multiFiltratePRO AR,
please visit
https://www.freseniusmedicalcare.com/en/ready4-multifiltratepro-ar.
About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products
and services for individuals with renal diseases of which around
3.9 million patients worldwide regularly undergo dialysis
treatment. Through its network of 4,000 dialysis clinics, Fresenius
Medical Care provides dialysis treatments for approximately 332,000
patients around the globe and is the leading provider of dialysis
products such as dialysis machines and dialyzers. Fresenius Medical
Care is listed on the Frankfurt Stock Exchange (FME) and on the New
York Stock Exchange (FMS).
For more information visit the Company's website
at www.freseniusmedicalcare.com.
Disclaimer:
This release contains forward-looking statements that are subject
to various risks and uncertainties. Actual results could differ
materially from those described in these forward-looking statements
due to various factors, including, but not limited to, changes in
business, economic and competitive conditions, legal changes,
regulatory approvals, impacts related to COVID-19, results of
clinical studies, foreign exchange rate fluctuations, uncertainties
in litigation or investigative proceedings, and the availability of
financing. These and other risks and uncertainties are detailed in
Fresenius Medical Care AG's reports filed with the U.S. Securities
and Exchange Commission. Fresenius Medical Care AG does not
undertake any responsibility to update the forward-looking
statements in this release.
Media contact
Christine
Peters
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com
Contact for analysts and investors
Dr.
Dominik Heger
T +49
6172 609
2601
dominik.heger@freseniusmedicalcare.com
www.freseniusmedicalcare.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-launches-augmented-reality-for-training-on-kidney-replacement-therapy-device-302091941.html
SOURCE Fresenius Medical Care Holdings, Inc.
